This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Abbott Laboratories at 52-Week High on Product Line, Buyouts
by Zacks Equity Research
Share price of IL-based Abbott Laboratories (ABT) scaled a new 52-week high of $46.55 on Jun 2, eventually closing a bit lower at $46.50.
The Zacks Analyst Blog Highlights: Alphabet, Morgan Stanley, Abbott, Waste Management, General Mills and Raytheon
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alphabet, Morgan Stanley, Abbott, Waste Management, General Mills and Raytheon
Abbott Labs (ABT) Down 2.3% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Abbott Labs (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights: General Dynamics, EOG Resources, Abbott, Northrop Grumman and Symantec
by Zacks Equity Research
The Zacks Analyst Blog Highlights: General Dynamics, EOG Resources, Abbott, Northrop Grumman and Symantec
Abbott Lab Well Poised on Strong EPD, St. Jude Integration
by Zacks Equity Research
On May 17, we issued an updated research report on Abbott Laboratories (ABT).
Company News for April 20, 2017
by Zacks Equity Research
Companies in the News are: LRCX,FB,RARE,ABT
Q1 Scorecard & Stock Research Reports for IBM, Abbott and others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including IBM (IBM), Abbott (ABT) and Dow Chemical (DOW).
Abbott (ABT) Tops Q1 Earnings on Strong EPD, Medical Device
by Zacks Equity Research
Abbott Laboratories (ABT) reported first-quarter 2017 adjusted earnings from continuing operations of 48 cents per share, up 17.1% year over year.
Abbott Laboratories (ABT) Tops Q1 Earnings & Sales Estimates
by Zacks Equity Research
Currently, Abbott Labs has a Zacks Rank #3 (Hold), but that could definitely change following the company's first quarter 2017 earnings report which was just released.
Company News for April 18, 2017
by Zacks Equity Research
Companies in the News are: MGI,LLY,ASH,ALR,ABT
Company News for April 17, 2017
by Zacks Equity Research
Companies in the News are: ABT,UAL,GS,PIR
Abbott Laboratories Agrees to Acquire Alere at Lower Price
by Zacks Equity Research
Abbott has agreed to pay $51 per common share to acquire Alere, a reduction from earlier deal of $56 per common share upon the completion of the transaction.
Will Abbott Lab (ABT) Surprise Estimates in Q1 Earnings?
by Zacks Equity Research
Abbott Laboratories (ABT) is scheduled to report first-quarter 2017 results before the opening bell on Apr 19.
Abbott's St Jude Buyout to Boost Business, Risks Remain
by Zacks Equity Research
On Mar 31, we updated our research report on medical device major, Abbott Laboratories (ABT).
Trump, Biogen and Amgen Hammer Healthcare ETFs
by Sweta Killa
After making a strong comeback in February, the U.S. healthcare sector again witnessed some pain in the last couple of sessions.
Abbott Laboratories' MitraClip Outcome Positive for DMR
by Zacks Equity Research
Abbott Laboratories (ABT) recently presented one-year positive outcomes from the study of the MitraClip system in transcatheter mitral valve repair (TMVR) procedures in the U.S.
Abbott Labs (ABT) Up 10.8% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Abbott Labs (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Acadia Healthcare (ACHC) Tops Q4 Earnings, Gives 2017 View
by Zacks Equity Research
Acadia Healthcare Company Inc. (ACHC) reported fourth-quarter 2016 adjusted earnings of 59 cents per share, which surpassed the Zacks Consensus Estimate by 4 cents.
Abbott Laboratories Gains Despite Unimpressive Q4 Revenue Results
by Parth Panchal
Abbott Laboratories (ABT) just released its fourth quarter fiscal 2016 earnings results, posting earnings of $0.65 per share and revenue of $5.33 billion.
Abbott Labs (ABT) Tops Q4 Earnings Estimates, Sales In Line
by Zacks Equity Research
Abbott Laboratories (ABT) reported fourth-quarter 2016 earnings from continuing operations of 65 cents per share, a penny higher than the Zacks Consensus Estimate.
Abbott Laboratories (ABT): Tops Q4 Earnings, Sales in Line
by Zacks Equity Research
Abbott Laboratories (ABT) earnings per share has beaten the Zacks Consensus Estimated while its revenues were almost in line with the mar.
3 Stocks with Great Earnings Charts
by Tracey Ryniec
Looking for stocks that beat on earnings nearly every quarter?
What's in Store for Abbott Labs (ABT) This Earnings Season?
by Zacks Equity Research
Abbott Laboratories (ABT) is scheduled to report fourth-quarter and full year 2016 results before the opening bell on Jan 25.
IDEXX Laboratories (IDXX) Set to Join the S&P 500 Index
by Zacks Equity Research
IDEXX Laboratories, Inc. (IDXX) is scheduled to join the coveted S&P 500 benchmark, after the market closes on Jan 4.
Abbott Labs to Close St. Jude Acquisition Later this Week
by Zacks Equity Research
Abbott Laboratories (ABT) announced to close the acquisition of St. Jude Medical, Inc., (STJ) on Jan 4, 2017.